$1.09
4.39%
Nasdaq, Sep 24, 04:00 pm EDT. Closed.
ISIN
US00091F1066
Symbol
ABVC

ABVC BioPharma Inc Stock price

$1.09
+0.25 29.76% 1M
-0.05 4.43% 6M
-1.06 49.30% YTD
-2.17 66.57% 1Y
+0.14 14.88% 3Y
-23.94 95.65% 5Y
-362.27 99.70% 10Y
-999,998.91 100.00% 20Y
Nasdaq, Closing price Thu, Sep 24 2026
-0.05 4.39%
ISIN
US00091F1066
Symbol
ABVC
Industry

Is ABVC BioPharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$34.0m
Enterprise Value
$34.7m
Net debt
$760.0k
Cash
$90.0k
Shares outstanding
25.8m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.3
Financial Health
Equity Ratio
52.8%
Return on Equity
-71.2%
ROCE
-53.3%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
$-7.3m
EBIT
$-7.3m
Net Income
$-7.9m
Free Cash Flow
$-2.7m
Growth (TTM | estimate)
Revenue
-100.0% | -
EBITDA
-144.6%
EBIT
-142.4%
Net Income
-158.2%
Free Cash Flow
-53.7%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-0.3
FCF per Share
$-0.1
Short interest
2.4%
Employees
18
Rev per Employee
$0.0

ABVC BioPharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a ABVC BioPharma Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a ABVC BioPharma Inc forecast:

Hold
50%
Sell
50%

Financial data from ABVC BioPharma Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.40 6.40
81% 81%
-
- Research and Development Expense 0.11 0.11
15% 15%
-
-7.29 -7.29
145% 145%
-
- Depreciation and Amortization 0.02 0.02
50% 50%
-
EBIT (Operating Income) EBIT -7.31 -7.31
142% 142%
-
Net Profit -7.90 -7.90
158% 158%
-

In millions USD.

Don't miss a Thing! We will send you all news about ABVC BioPharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of new drugs and medical devices. The company also integrates research achievements from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. It conducts clinical trials of translational medicine for Proof of Concept and out-licenses it to international pharmaceutical companies. Its products include BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia. The company was founded in 1990 and is headquartered in Fremont, CA.

Head office United States
CEO Dr. Patil
Employees 18
Founded 1990
Website abvcpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today